CYP2A6 rs28399499: Understanding Nicotine Metabolism Genetics
The rs28399499 variant is a genetic marker located within the CYP2A6 gene, which plays a primary role in how the body breaks down nicotine. This specific variant is associated with the CYP2A6*2 allele, which is known to result in reduced enzyme activity and slower nicotine clearance.
What each genotype means
Normal nicotine metabolism
This genotype is associated with typical CYP2A6 enzyme activity, which is the primary catalyst for nicotine oxidation in the liver. Individuals with this profile generally exhibit standard rates of nicotine clearance. If you are considering nicotine replacement therapy or smoking cessation aids, please discuss your specific needs with a clinician or pharmacist.
This is the most common genotype across most global populations.
Reduced nicotine metabolism
This genotype includes one copy of the variant associated with the CYP2A6*2 allele, which is known to cause defective nicotine C-oxidation. You may experience slower metabolic clearance of nicotine compared to individuals without this variant. Please consult with your healthcare provider or pharmacist regarding how this may influence your response to nicotine-related medications or smoking cessation strategies.
Carried by roughly 2% to 6% of people of European ancestry; it is very rare or absent in African and Asian populations.
Slow nicotine metabolism
This genotype consists of two copies of the variant associated with the CYP2A6*2 allele, which is a recognized loss-of-function variant resulting in significantly reduced enzyme activity. This can lead to slower nicotine metabolism and altered clearance rates. Because this may affect how your body processes nicotine or certain medications, please discuss your health profile and any treatment plans with your clinician or pharmacist.
This genotype is very rare, occurring in less than 1% of individuals in European populations and is essentially absent in most other ancestral groups.
What is the rs28399499 Variant?
The rs28399499 variant is a single nucleotide polymorphism (SNP) situated within the CYP2A6 gene. In the context of genetic research, this SNP serves as a defining marker for the CYP2A6*2 allele. The CYP2A6 gene provides instructions for creating an enzyme that is responsible for the majority of nicotine metabolism in the human liver. When a person carries the *2 allele, the resulting enzyme often exhibits defective nicotine C-oxidation, which is the chemical process of breaking down nicotine into its primary metabolite, cotinine. Because this variant alters the structure or function of the enzyme, it is frequently studied in the field of pharmacogenetics to understand why individuals process nicotine at different rates. By identifying this specific SNP, researchers can categorize individuals based on their predicted metabolic capacity, which is a key factor in studying how nicotine affects the body.
The Role of the CYP2A6 Gene
The CYP2A6 gene belongs to the cytochrome P450 family, a group of enzymes essential for the metabolism of various endogenous compounds, such as steroids and retinoid acids, as well as exogenous substances like drugs and toxins. Specifically, CYP2A6 is responsible for approximately 70% to 80% of the initial metabolism of nicotine. Because of this high level of involvement, the gene is a major focus for scientists investigating tobacco dependence and smoking cessation. Variations in this gene can lead to significant interindividual differences in enzyme activity, ranging from very low to very high. These differences are not just academic; they influence how long nicotine remains in the bloodstream, which can impact a person's urge to smoke and their overall nicotine intake. Understanding the function of this gene is critical for researchers looking to develop personalized approaches to smoking cessation and to better understand the biological underpinnings of tobacco use.
Research and Evidence Strength
Research into rs28399499 and the associated CYP2A6*2 allele has established a clear link between this genetic variation and reduced nicotine metabolic activity. However, the overall evidence strength for its clinical application remains limited. While many studies have demonstrated that carriers of reduced-function alleles may smoke fewer cigarettes or show different patterns of nicotine dependence, the results can be inconsistent across different populations. The complexity of smoking behavior, which is influenced by both genetic and environmental factors, makes it difficult to isolate the effect of a single SNP. Furthermore, because there are dozens of known variants in the CYP2A6 gene, the *2 allele is only one piece of a much larger puzzle. Current scientific consensus suggests that while this variant is a valid marker for metabolic speed, more research is needed to determine how it should be used in clinical practice or public health interventions.
What You Can Do With This Information
It is important to understand that genetic information regarding rs28399499 is for educational purposes and should not be used to make medical decisions. Knowing your genotype for this variant does not provide a diagnosis or a definitive prediction of how you will respond to nicotine or any specific medication. If you are interested in how your genetics might influence your health or your response to smoking cessation aids, the most appropriate step is to consult with a healthcare professional or a pharmacist. They can provide context based on your full medical history and current clinical guidelines. Never attempt to adjust medications or change health behaviors based solely on genetic test results without professional guidance. Genetic markers are just one factor in a person's overall health profile, and they should always be interpreted within the broader context of your lifestyle and clinical care.
How common is this variant?
The minor allele frequency for this variant is approximately 0.01 to 0.03 in European ancestries, while it is considered very rare or absent in African and Asian populations.
Frequently asked questions
Does having the rs28399499 variant mean I am addicted to nicotine?
No, this variant is not a diagnostic tool for addiction. It is a genetic marker associated with how quickly your body metabolizes nicotine, which is only one of many factors that contribute to smoking behavior and dependence.
Can I use this genetic information to quit smoking?
Genetic information can provide insight into your metabolism, but it is not a substitute for evidence-based smoking cessation programs. You should discuss your cessation goals with a doctor or pharmacist who can recommend strategies tailored to your health needs.
Is the rs28399499 variant common in all populations?
No, the frequency of this variant varies significantly by ancestry. It is most commonly observed in European populations and is very rare or absent in many African and Asian populations.
Should I get tested for CYP2A6 variants?
Routine genetic testing for CYP2A6 variants is not currently standard clinical practice for the general public. If you have concerns about medication metabolism or smoking cessation, consult your healthcare provider to see if such testing is relevant to your specific situation.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs28399499?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2A6
Functional splice-site variant defining CYP2A6*20 associated with significantly reduced enzyme activity and slower nicotine and coumarin clearance.
Defines the non-functional CYP2A6*2 allele (p.Leu160His) conferring absent nicotine C-oxidation activity and slow nicotine metabolism.
Functional variant in CYP2A6 defining the *9 allele with decreased transcriptional activity and reduced rate of nicotine metabolism.
Associated with the CYP2A6 locus and variation in rate of nicotine metabolism and cigarette consumption.
Functional polymorphism defining the CYP2A6*9 reduced-function promoter variant causing slower nicotine and cotinine metabolism.
Defining coding polymorphism for CYP2A6*8 (p.Arg365Gln), resulting in significantly decreased catalytic activity towards substrate medications including tegafur.